This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Chemours (CC) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of 25% and 5.32%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
LyondellBasell (LYB) Q3 Earnings Miss Estimates
by Zacks Equity Research
LyondellBasell (LYB) delivered earnings and revenue surprises of -7.39% and 0.49%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
DuPont de Nemours (DD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
DuPont de Nemours (DD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Chemours (CC) Q3 Earnings Expected to Decline
by Zacks Equity Research
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dow Inc. (DOW) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Dow Inc. (DOW) delivered earnings and revenue surprises of 2.17% and 1.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Chemours Develops Low GWP Retrofit Approach for Vehicles
by Zacks Equity Research
CC anticipates its Opteon portfolio to save an estimated 325 million tons of carbon dioxide equivalent by 2025.
Chemours (CC) Opens Cutting-Edge Facility for EV Batteries
by Zacks Equity Research
Chemours (CC) opens the Chemours Battery Innovation Center to advance sustainable battery technology for electric vehicles.
Chemours (CC) Earnings Miss, Revenues Beat Estimates in Q2
by Zacks Equity Research
Chemours' (CC) earnings miss estimates in the second quarter due to lower selling prices.
Chemours (CC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Chemours (CC) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Chemours (CC) Misses Q2 Earnings Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of -42.42% and 0.01%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Can These 4 Chemical Stocks Hit Targets This Earnings Season?
by Anindya Barman
Chemical companies are expected to have benefited from demand recovery across key end markets and moderated de-stocking activities. Let's see how APD, CE, CC and AXTA are poised ahead of their earnings releases.
Do Options Traders Know Something About Chemours (CC) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Chemours (CC) stock based on the movements in the options market lately.
Analysts Estimate LyondellBasell (LYB) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
LyondellBasell (LYB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Chemours (CC) Q2 Earnings Expected to Decline
by Zacks Equity Research
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemours (CC) Soars 5.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Chemours (CC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Chemours (CC) Announces Enhancement of EVOLVE 2030 Methodology
by Zacks Equity Research
The revised EVOLVE 2030 approach improves Chemours' (CC) ability to integrate its business processes with this goal.
Why Is Chemours (CC) Down 2.1% Since Last Earnings Report?
by Zacks Equity Research
Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Chemours (CC) Earnings Beat, Revenues Miss Estimates in Q1
by Zacks Equity Research
Lower volumes and prices hurt Chemours' (CC) top line in the first quarter.
Chemours (CC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Chemours (CC) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Chemours (CC) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of 28% and 0.76%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Chemours (CC) Up 2.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Stepan Co. (SCL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Stepan Co. (SCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Chemours (CC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemours (CC) Recently Broke Out Above the 20-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
Chemours (CC) Just Reclaimed the 50-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?